Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- Government Perspectives on Mobility and the Cloud
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Reimagining the Next Generation of Government
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
6 European countries pull Novartis flu vaccines
Friday - 10/26/2012, 1:44pm EDT
BERLIN (AP) - Six European countries have ordered a temporary ban on the import or use of some Novartis flu vaccines.
Austria, France, Germany, Italy, Spain and Switzerland have limited the use of Fluad or Aggripal, or both, after the company reported the appearance of small particles in the vaccine to Italian authorities.
Italian health officials say the company knew of the problem since July but only notified them this month.
Novartis spokesman Eric Althoff declined to specify Friday how long the Basel, Switzerland-based pharmaceutical giant waited before telling authorities.
In an email, Althoff said that "once the deviation was seen, an investigation was started and the findings were shared with the Italian Ministry of Health."
Other flu vaccines are available in the affected countries but delivery bottlenecks are expected in some regions.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)